Biopharmaceutical company Gilead Sciences Inc (Nasdaq:GILD) on Thursday released topline results from an interim analysis of a Phase 3 trial indicating that the company's twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, is more effective in preventing HIV infection in women compared to its existing daily pill, Truvada.
Gilead said that there were zero cases of HIV infection among women who were treated with lenacapavir. More detailed data will be presented at a later date.
Truvada, a combination of tenofovir and emtricitabine, can treat HIV and is also used in a prevention regimen known as pre-exposure prophylaxis (PrEP).
Ananda's cannabinoid medicines to feature in NHS epilepsy trials
AstraZeneca's Wainzua recommended for EU approval
Avacta Group partners with Tempus to enhance AI-driven oncology drug development
PharmaLogic opens new radiopharmaceutical facility in Salt Lake City
Astellas Pharma's VYLOY receives US FDA approval
Foresee Pharmaceuticals completes linvemastat (FP-020) phase clinical study in Australia
Ionis and AstraZeneca's WAINZUA recommended for EU approval
Novartis receives positive CHMP opinion for Kisqali
OncoZenge partners with Pharmanovia for exclusive BupiZenge commercialization in EMENA regions
SHINE Technologies collaboration could result in new kidney and prostate cancer treatments
Elysium Health launches VISION for visual performance and eye health
IgGenix doses first patient in IGNX001 ACCELERATE Peanut Phase 1 trial
Innovent Biologic meets primary endpoint in picankibart phase 2 study